Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1827 • 2019 ACR/ARP Annual Meeting
Clinical Implications of Neutrophil Extracellular Traps in Systemic Lupus Erythematosus
Stanley Moore ¹, Hsin-Hsuan Juo ¹, Christoffer Nielsen ², Helena Tyden ³, Anders Bengtsson ³ and Christian Lood¹, ¹University of Washington, Seattle, ²Statens Serum Institut, Copenhagen, Denmark, ³Lund University, Lund, Sweden
Background/Purpose: Neutrophil activation, including formation of neutrophil extracellular traps (NETs), is essential in host defense. However, NET formation has also been linked to inflammation and…
Abstract Number: 2035 • 2019 ACR/ARP Annual Meeting
Systemic Lupus Erythematosus (SLE) Is Caused by Expanded DOCK8-Positive Autoantibody-Inducing CD4 T (aiCD4 T) Cell
Shunichi Shiozawa¹, Ken Tsumiyama ¹, Yumi Miyazaki ², Keiichi Sakurai ³, Takahiko Horiuchi ⁴, Motohiro Oribe ⁵, Takashi Yamane ⁶, Hidetoshi Kagawa ⁷ and Kazuko Shiozawa ⁸, ¹Institute for Rheumatic Diseases, Ashiya, Japan, ²Kyushu University Beppu Hospital, Tokyo, Japan, ³Rheumatology and Allergology, St. Marianna University School of Medicine, Tokyo, Japan, ⁴Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, Beppu, Japan, ⁵Oribe Rheumatology Clinic, Oita, Japan, ⁶Department of Rheumatology, Kakogawa Central City Hospital, Kakogawa, Japan, ⁷Rheumatology, Red Cross Society Himeji Hospital, Himeji, Japan, ⁸Rheumatic Diseases Center, Hyogo Prefectural Kakogawa Medical Center, Ashiya, Japan
Background/Purpose: We previously found in reproducible experiments in which the mice not prone to autoimmune disease were immunized repeatedly with antigen that overstimulation of CD4…
Abstract Number: 2521 • 2019 ACR/ARP Annual Meeting
Rituximab Treatment Is Not Associated with Increased Risk of Infection or Mortality in Refractory SLE Patients: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)
Stephen McDonald¹, Eoghan McCarthy ², Aysun Aksoy ³, Ben Parker ⁴ and Ian Bruce ⁵, ¹University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom; Manchester University Foundation Trust, The Kellgren Centre, Manchester, United Kingdom, Belfast, Northern Ireland, United Kingdom, ²Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, England, United Kingdom, ³Marmara University Faculty of Medicine, Division of Internal Medicine, Department of Rheumatology, Istanbul, Turkey; University of Manchester, Division of Musculoskeletal and Dermatological Sciences, Manchester, United Kingdom, Istanbul, Istanbul, Turkey, ⁴University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom; Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, United Kingdom, ⁵University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom
Background/Purpose: Mortality in Systemic Lupus Erythematosus (SLE) is increased compared to the general population. We sought to investigate mortality rates and associated factors in a…
Abstract Number: 2554 • 2019 ACR/ARP Annual Meeting
Do All Patients Who Achieve Lupus Low Disease Activity State Have Similar Outcomes?
Konstantinos Tselios¹, Dafna Gladman ², Jiandong Su ³ and Murray Urowitz ¹, ¹University Health Network, University of Toronto, Toronto, Canada, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Lupus Low Disease Activity State (LLDAS) has been associated with favourable outcomes in systemic lupus erythematosus (SLE). However, the complexity of its defining criteria…
Abstract Number: 2783 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Blood Levels and Risk of Thrombotic Events in Systemic Lupus Erythematous
Maximlian Konig¹, Jessica Li ¹ and Michelle Petri ¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The antimalarial drug hydroxychloroquine (HCQ) has a primary role in the treatment of systemic lupus erythematous (SLE). Beyond its pleiotropic immunomodulatory effects on TLR…
Abstract Number: 69 • 2019 ACR/ARP Annual Meeting
Treatment of Lupus-prone MRL-lpr Mice with the Mitochondrial Antioxidant MitoQ
Ralph Budd¹, Karen Fortner ¹, Luz Blanco ², Mariana Kaplan ³, Andras Perl ⁴, Iwona Busliewicz ⁵, Greg MacPherson ⁶ and Mike Murphy ⁷, ¹The University of Vermont Larner College of Medicine, Burlington, VT, ²NIH NIAMS, Bethesda, MD, ³National Institute of Arthritis, Musculoskeletal, and Skin diseases/ National Institutes of Health, Bethesda, ⁴SUNY Upstate Medical University, Syracuse, NY, ⁵Upstate Medical Center, Syracuse, NY, ⁶MitoQ, Aukland, New Zealand, ⁷Wellcome MRC Mitochondrial Biology Unit, Cambridge, United Kingdom
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by a type I Interferon (IFN-I) gene signature in peripheral blood lymphocytes (PBL), which contain enlarged mitochondria and…
Abstract Number: 639 • 2019 ACR/ARP Annual Meeting
African-American Risk of Proteinuria After SLE Diagnosis Increases Throughout Thirty Years of Followup
Michelle Petri¹ and Jessica Li ¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: African-Americans lupus nephritis is more common than in Caucasians, more severe and more likely to lead to end stage renal disease. We asked whether…
Abstract Number: 697 • 2019 ACR/ARP Annual Meeting
Differing Opinions on Clinical Research Between Healthcare Providers and Lupus Patients
Cristina Arriens¹, Dylan Forciea ², Judith James ¹ and Joan T. Merrill ³, ¹Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oseberg, Oklahoma City, OK, ³Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Although SLE disproportionately affects minority racial groups, this population is significantly under-represented in clinical trials, increasing risk for underpowered, incorrect conclusions in race-based sub-group…
Abstract Number: 1018 • 2019 ACR/ARP Annual Meeting
Renal Single Cell Genomics Links Type II Interferon and Lupus Nephritis in African-Americans
Andrea Fava¹, Yuji Zhang ², Jill Buyon ³, Chaim Putterman ⁴, Nir Hacohen ⁵, Arnon Arazi ⁵, Celine Berthier ⁶, Deepak Rao ⁷, Michael Brenner ⁸, David Wofsy ⁹, Anne Davidson ¹⁰, Mathias Kretzler ¹¹, David Hildeman ¹², E. Steve Woodle ¹², Betty Diamond ¹⁰, Thomas Tuschl ¹³, Evan Der ¹⁴, Hemant Suryawanshi ¹³, H. Michael Belmont ¹⁵, Peter Izmirly ¹⁶, Robert Clancy ¹⁶, The Accelerating Medicines Partnership ¹⁷ and Michelle Petri ¹⁸, ¹Johns Hopkins University, Baltimore, ²University of Maryland, Baltimore, ³NYU School of Medicine, New York, ⁴Albert Einstein College of Medicine, New York, NY, ⁵Broad Institute, Cambridge, ⁶University of Michigan, Ann Arbor, MI, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Brigham and Women’s Hospital:, Boston, ⁹UCSF, San Francisco, ¹⁰Feinstein Institutes for Medical Research, Manhasset, ¹¹University of Michigan, Ann Arbor, ¹²University of Cincinnati, Cincinnati, ¹³Rockefeller Research Laboratories, New York, ¹⁴Albert Einstein College of Medicine, New York, ¹⁵New York University School of Medicine, Ney York, ¹⁶New York University School of Medicine, New York, ¹⁷Multiple Organizations, USA, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Compared to Caucasian, African-American ethnicity is associated with a higher risk of developing systemic lupus erythematosus, lupus nephritis, high-risk histological features, resistance to treatment,…
Abstract Number: 1146 • 2019 ACR/ARP Annual Meeting
Therapy of Lupus Nephritis with Mycophenolate Mofetil in Routine Clinical Practice: Response Rates and Role of Ethnicity
Prathima Anandi ¹, Alyson Dickson ², Vivian Kawai ², C. Michael Stein ² and Cecilia Chung³, ¹Vanderbilt University Medical Center, Nashville, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University, Nashville, TN
Background/Purpose: Randomized clinical trials have reported that 56-68% of patients with lupus nephritis treated with mycophenolate mofetil (MMF) respond to therapy, and a randomized clinical…
Abstract Number: 1577 • 2019 ACR/ARP Annual Meeting
The Impact of the New American College of Cardiology/American Heart Association Definition of Hypertension on Cardiovascular Events in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna Gladman ², Jiandong Su ³ and Murray Urowitz ⁴, ¹University Health Network, University of Toronto, Toronto, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University Health Network, University of Toronto, Toronto, Canada
Background/Purpose: The 2017 guidelines by the American College of Cardiology/American Heart Association (ACC/AHA) define hypertension at a threshold of ≥130/80mmHg for the systolic and diastolic…
Abstract Number: 1619 • 2019 ACR/ARP Annual Meeting
Early Vascular Ageing as a Predictor of Future Cardiovascular Events and Mortality in Systemic Lupus Erythematosus Patients: A Prospective Cohort Study
Viola Signorini¹, Dina Zucchi ², Chiara Tani ³, Rosa Maria Bruno ⁴, Elena Elefante ³, Chiara Stagnaro ⁵, Linda Carli ³, Alice Parma ³, Francesco Ferro ⁶, Sabina Armenia ⁷, lorenzo Ghiadoni ⁸, Stefano Taddei ⁷ and Marta Mosca ³, ¹Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, pisa, Toscana, Italy, ²Rheumatology Unit. Department of clinical and experimental medicine, University of PIsa, Pisa, Toscana, Italy, ³Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, ⁴Hypertension Unit, Department of clinical e experimental medicine, University di Pisa, Pisa, Italy, ⁵Azienda Ospedaliero Universitaria Pisana, University of Pisa, Pisa, Italy, ⁶Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, Pisa, Italy, ⁷Hypertension Unit, Department of clinical and experimental medicine, University of Pisa, pisa, Italy, ⁸Emergency Unit, Department of clinical and experimental medicine, University of Pisa, pisa, Italy
Background/Purpose: Systemic Lupus Erithematosus (SLE) is associated with increased cardiovascular (CV) risk compared with general population; an accelerated atherosclerosis is considered the main underlying mechanism.…
Abstract Number: 1845 • 2019 ACR/ARP Annual Meeting
Physical Inactivity Is a Risk Factor for Incident Depression in Systemic Lupus Erythematosus
Laura Trupin¹, Sarah Patterson ¹, Louise Murphy ², Maria Dall'Era ¹, Jinoos Yazdany ³ and Patricia Katz ¹, ¹University of California, San Francisco, San Francisco, CA, ²Centers for Disease Control and Prevention, Division of Population Health, Atlanta, ³UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: Physical activity can prevent and reduce depression, but there is little research on the relationship between physical inactivity and subsequent onset of depression in…
Abstract Number: 2038 • 2019 ACR/ARP Annual Meeting
Antibodies to Malondialdehyde-acetaldehyde (MAA) Protein Adduct as a Biomarker for Cardiovascular Manifestations in Systemic Lupus Erythematosus
Yangsheng Yu ¹, Michelene Hearth-Holmes ², Tammy Wang ¹, Perio D Lopez ³, Carmen Tineo ⁴, G Paulino ⁴, Michael Duryee ², Geoffrey Thiele ⁵, Ted Mikuls ⁵, Esthela Loyo ⁴ and Kaihong Su², ¹University of Nebraska Medical Center, Omaha, ²University of Nebraska Medical Center, Omaha, NE, ³Georgetown University, Washington DC, ⁴Hospital Regional Universitario José Ma Cabral Baez, San Diego, Dominican Republic, ⁵VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by devastating end-organ manifestations. Cardiovascular disease (CVD) is a leading cause for premature death…
Abstract Number: 2522 • 2019 ACR/ARP Annual Meeting
Frequency and Early Prediction of Hydroxychloroquine Induced Retinopathy in SLE
Jessica Li¹, Daniel Goldman ² and Michelle Petri ¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: In 2016, the American Academy of Ophthalmology (AAO) published recommendations designed to reduce hydroxychloroquine induced retinopathy via early detection and reduction of hydroxychloroquine dosing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].